Athersys, Inc. (NASDAQ:ATHX) most recently reported quarterly actual earnings per share of $-0.08 for the period ending on 2016-06-30. Prior to the company reporting, consensus estimates based on data from Zacks Research projected the company to report EPS of $-0.1. The difference between the estimate and the actual EPS was $0.02 creating a surprise factor of 20%. Currently, the company has an impact score of 0. The likelihood that the stock will move on news is greater with a higher impact score. According to Beta Research, the stock has a sentiment score of 0.435. On a scale between 1 and -1, a positive score tends to portray a favorable view of company results by news outlets. The opposite is true for a negative sentiment score.

In taking a look at where the stock might be headed, analysts have a consensus price target of $4.333 on the shares. The most bullish brokerage firm has a $10 target, while the most bearish sees the stock headed towards $1. This is according to the 3 estimates taken into consideration by Zacks Research.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 1.67. This is according to a simplified scale where 1 represents a Strong Buy and 5 a Strong Sell recommendation. There were 3 recommendations taking into account in order to arrive at this number. Of the 3, 2 have a Strong Buy rating and 0 are rating it a Buy.

Athersys Inc. is a biopharmaceutical company engaged in the field of regenerative medicine. During the year ended December 31, 2011 the Company is developing its platform product, MultiStem, a allogeneic stem cell product that has been evaluated in two completed Phase I clinical trials and as of December 31, 2011, is being evaluated in two ongoing Phase II clinical trials. The Company’s clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The Company is also engaged in the development of small molecule therapies to treat obesity and other conditions. During 2011, the Company is focused on the development of potent, highly selective compounds that act through stimulation of a specific receptor in the brain that controls appetite, the 5HT2c serotonin receptor.

Athersys, Inc. - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with’s FREE daily email newsletter.